Arid5a: A missing link between EMT and tumoral immune resistance by Van den Eynde, BJ

Combining personalized neoantigen vaccination with chemotherapy and anti-PD-1 to treat NSCLC by Leung, CSK, Van den Eynde, BJ

Uncovering molecular actors of IDO-mediated T cell dysfunction with genome-wide CRISPR/Cas9 knockout screens by Bombart, R, Zhu, J, van den Eynde, BJ

Editorial: Heme proteins: key players in the regulation of immune responses by Volpi, C, Van den Eynde, BJ, Orabona, C

Systemic tryptophan homeostasis by Klaessens, S, Stroobant, V, De Plaen, E, Van den Eynde, BJ

Functional differences between proteasome subtypes by Abi Habib, J, Lesenfants, J, Vigneron, N, Van den Eynde, BJ

Preclinical murine tumor models: a structural and functional perspective by Guerin, MV, Finisguerra, V, Van den Eynde, BJ, Bercovici, N, Trautmann, T

Tryptophan 2,3-dioxygenase expression identified in murine decidual stromal cells is not essential for feto-maternal tolerance by Hoffmann, D, Dvorakova, T, Schramme, F, Stroobant, V, Van den Eynde, BJ

TGFβ1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism by Canè, S, Van Snick, J, Uyttenhove, C, Pilotte, L, Van den Eynde, BJ

Navigating critical challenges associated with immunopeptidomics-based detection of proteasomal spliced peptide candidates by Lichti, CF, Vigneron, N, Clauser, KR, Van den Eynde, BJ, Bassani-Sternberg, M

Tumour immune rejection triggered by activation of α2-adrenergic receptors by Zhu, J, Naulaerts, S, Boudhan, L, Martin, M, Gatto, L, Van den Eynde, BJ

Enhanced tumor response to adoptive T cell therapy with PHD2/3-deficient CD8 T cells by Dvorakova, T, Finisguerra, V, Formenti, M, Loriot, A, Boudhan, L, Zhu, J, Van den Eynde, BJ

Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytoma by Lopes, A, Vanvarenberg, K, Kos, S, Lucas, S, Colau, D, Van Den Eynde, BJ, Préat, V, Vandermeulen, G

Constitutive IDO1 expression in human tumors is driven by cyclooxygenase-2 and mediates intrinsic immune resistance by Hennequart, M, Pilotte, L, Cane, S, Hoffmann, D, Stroobant, V, De Plaen, E, Van Den Eynde, BJ

Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression by Finisguerra, V, Dvorakova, T, Formenti, M, Van Meerbeeck, P, Mignion, L, Gallez, B, Van den Eynde, BJ

Tryptophanemia is controlled by a tryptophan-sensing mechanism ubiquitinating tryptophan 2,3-dioxygenase by Klaessens, S, Stroobant, V, Hoffmann, D, Gyrd-Hansen, M, Pilotte, L, Vigneron, N, De Plaen, E, Van den Eynde, BJ

Efficiency of the four proteasome subtypes to degrade ubiquitinated or oxidized proteins by Abi Habib, J, De Plaen, E, Stroobant, V, Zivkovic, D, Bousquet, M-P, Guillaume, B, Wahni, K, Messens, J, Busse, A, Vigneron, N, Van den Eynde, BJ

Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression by Ramirez-Valdez, RA, Baharom, F, Khalilnezhad, A, Fussell, SC, Hermans, DJ, Schrager, AM, Tobin, KKS, Lynn, GM, Khalilnezhad, S, Ginhoux, F, Van den Eynde, BJ, Leung, CSK, Ishizuka, AS, Seder, RA

Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy by McAuliffe, J, Chan, HF, Noblecourt, L, Ramirez-Valdez, RA, Pereira-Almeida, V, Zhou, Y, Pollock, E, Cappuccini, F, Redchenko, I, Hill, AV, Leung, CSK, Van den Eynde, BJ

Tryptophan 2,3-dioxygenase expression identified in human hepatocellular carcinoma cells and in intratumoral pericytes of most cancers by Hoffmann, D, Dvorakova, T, Stroobant, V, Bouzin, C, Daumerie, A, Solvay, M, Klaessens, S, Letellier, M-C, Renauld, J-C, van Baren, N, Lelotte, J, Marbaix, E, Van den Eynde, BJ